樂觀
$835.20
情境價格
$1,015.500
-14.420 (-1.42%)收盤時
McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions.
McKesson Corp is a strong buy at the current price of $1,004.84, especially given the recent 5-day change of +7.03% and a robust RSI of 90.185, indicating strong momentum. The forward P/E ratio of 19.72 suggests the stock is reasonably valued for its growth potential. However, the main risk is the insider selling, which has increased by 144.45% over the last month, indicating potential concerns among insiders about the stock's future performance.
BofA
—
2026-10-01
BofA
2026-10-01
目標價
—
RBC Capital
$845
2026-08-19
RBC Capital
2026-08-19
目標價
$845
Barclays
$925
2026-08-19
Barclays
2026-08-19
目標價
$925
Wells Fargo
$933
2026-08-11
Wells Fargo
2026-08-11
目標價
$933
Evercore ISI
$860
2026-08-06
Evercore ISI
2026-08-06
目標價
$860
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Investment Insights: Focus on McKesson and Medtronic

US Stocks Decline Due to Inflation Data

Option Care Health Shares Surge on Acquisition News

Tech Stocks Volatility and Investment Outlook

Market Recap: Strong Performances from CrowdStrike and GE Vernova
McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions. It operates in the Healthcare sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).
McKesson Corp is a strong buy at the current price of $1,004.84, especially given the recent 5-day change of +7.03% and a robust RSI of 90.185, indicating strong momentum. The forward P/E ratio of 19.72 suggests the stock is reasonably valued for its growth potential. However, the main risk is the insider selling, which has increased by 144.45% over the last month, indicating potential concerns among insiders about the stock's future performance.
14 analysts cover MCK: 4 rate it Buy, 9 Hold and 1 Sell. The average price target is 942.83.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。